Patents-Review.com
🔗 Permalink
Assignee profile:

IMCLONE LLC

City:

New York, New York

Country:

United States

Published Applications:

21

Last publication date:

2012-08-30

Patent Grants:

20

Last grant date:

2013-03-26

Top Inventors for applications by IMCLONE LLC

These are the the leading inventors for applications assigned to IMCLONE LLC:

Recent patent applications by IMCLONE LLC

IMCLONE LLC based in New York, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2012-08-30 ✅ Patent 8,404,240 granted on 2013-03-26
US20120219563A1
Chemistry; metallurgy

Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment

 #2 | 2012-05-17 ✅ Patent 8,263,074 granted on 2012-09-11
US20120121609A1
Chemistry; metallurgy

Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

 #3 | 2012-02-09 ✅ Patent 8,425,911 granted on 2013-04-23
US20120034244A1
Human necessities

Methods of treating secondary bone tumors with antibodies against PDGFR alpha

 #4 | 2012-02-02 ✅ Patent 8,574,578 granted on 2013-11-05
US20120027767A1
Human necessities

Antibodies against PDGFRα to inhibit tumor growth

 #5 | 2012-01-12 ✅ Patent 8,182,815 granted on 2012-05-22
US20120009200A1
Chemistry; metallurgy

Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment

 #6 | 2011-11-03 ✅ Patent 8,143,025 granted on 2012-03-27
US20110269186A1
Chemistry; metallurgy

Antibodies against vascular endothelial growth factor receptor-1

 #7 | 2011-06-09 ✅ Patent 8,133,489 granted on 2012-03-13
US20110135631A1
Chemistry; metallurgy

Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof

 #8 | 2011-01-13 ✅ Patent 8,071,099 granted on 2011-12-06
US20110008355A1
Chemistry; metallurgy

Anti-FLT3 antibodies

 #9 | 2010-09-02
US20100221267A1
Chemistry; metallurgy

PDGFR BETA-SPECIFIC INHIBITORS

 #10 | 2010-06-24 ✅ Patent 7,968,093 granted on 2011-06-28
US20100158920A1
Chemistry; metallurgy

Fully human antibodies directed against the human insulin-like growth factor-1 receptor

 #11 | 2010-05-13 ✅ Patent 8,147,834 granted on 2012-04-03
US20100119516A1
Chemistry; metallurgy

Anti-TGF-beta receptor II antibodies

 #12 | 2010-04-22 ✅ Patent 8,043,618 granted on 2011-10-25
US20100098696A1
Chemistry; metallurgy

Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment

 #13 | 2010-02-04 ✅ Patent 7,972,596 granted on 2011-07-05
US20100028347A1
Chemistry; metallurgy

Antibodies against vascular endothelial growth factor receptor-1

 #14 | 2009-09-17 ✅ Patent 7,951,370 granted on 2011-05-31
US20090232823A1
Chemistry; metallurgy

Anti-TYRP1 antibodies

 #15 | 2009-07-09 ✅ Patent 7,972,600 granted on 2011-07-05
US20090175868A1
Human necessities

IGF-IR antagonists as adjuvants for treatment of prostate cancer

 #16 | 2009-06-04 ✅ Patent 8,057,791 granted on 2011-11-15
US20090142358A1
Chemistry; metallurgy

Human antibodies specific to KDR and uses thereof

 #17 | 2009-05-28 ✅ Patent 7,947,811 granted on 2011-05-24
US20090136510A1
Chemistry; metallurgy

Antibodies that bind specifically to human RON protein

 #18 | 2009-04-30 ✅ Patent 8,128,929 granted on 2012-03-06
US20090110678A1
Human necessities

Antibodies against PDGFRa

 #19 | 2009-02-26 ✅ Patent 7,740,850 granted on 2010-06-22
US20090053241A1
Chemistry; metallurgy

PDGFRβ-specific antibodies

 #20 | 2008-01-31 ✅ Patent 7,638,605 granted on 2009-12-29
US20080025990A1
Chemistry; metallurgy

Fully human antibodies directed against the human insulin-like growth factor-1 receptor

 #21 | 2007-11-15 ✅ Patent 7,598,350 granted on 2009-10-06
US20070264253A1
Chemistry; metallurgy

Human anti-epidermal growth factor receptor antibody
AssigneeID:

202286 ⎘